2 recruiting, 2 unknown, 1 not yet recruiting, 1 terminated. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Multiple Myeloma Progression: new trials by email Literature Review of Multiple Myeloma Progression trials Research Report on Multiple Myeloma Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) Allogeneic, off-the-shelf CAR-T cell injection targeting BCMA and GPRC5D - Multiple Myeloma Refractory, Multiple Myeloma Progression | Phase 1 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 16 | 2026-06-01 | 2026-06-03 |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma KLN-1010 - Multiple Myeloma in Relapse, Myeloma Multiple | Phase 1 | Recruiting | Kelonia Therapeutics, Inc. | 70 | 2025-07-16 | 2026-08-28 |
| Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma BCMA/GPRC5D CAR-T cells - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-04-29 | 2025-06-22 |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors 225Ac-DOTATATE - Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Withdrawn | Jules Bordet Institute | 2024-10-01 | 2025-01-31 | |
| Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM anti-CD19/BCMA CAR-T cells, Fludarabine, Cyclophosphamide - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 1 | Unknown | Peng Liu | 20 | 2018-10-30 | 2018-10-16 |
| Tinostamustine Conditioning and Autologous Stem Cell Tinostamustine, Autologous Stem Cell Transplant (ASCT) - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 1 / Phase 2 | Terminated | Mundipharma-EDO GmbH | 6 | 2018-10-15 | 2021-06-18 |
| CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma CAR-T Re-treatment - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Unknown | Second Affiliated Hospital of Xi'an Jiaotong University | 20 | 2018-07-26 | 2018-12-14 |
Multiple Myeloma (4) · Autoimmune Diseases (1) · Blood Protein Disorders (1) · Disease (1) · Hematologic Diseases (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Vascular Diseases (1)
Cardiovascular Diseases (4) · Hemic and Lymphatic Diseases (4) · Hemorrhagic Disorders (4) · Blood Protein Disorders (3) · Hematologic Diseases (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Vascular Diseases (3) · Lymphatic Diseases (1)
Cyclophosphamide (1) · fludarabine (1) · tinostamustine (1)
Essen Biotech (1) · Jules Bordet Institute (1) · Kelonia Therapeutics, Inc. (1) · Mundipharma-EDO GmbH (1) · Peng Liu (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1) · Zhongshan Hospital (Xiamen), Fudan University (1)
China (3) · United States (2) · Australia (1) · Belgium (1) · Norway (1) · Switzerland (1)
Dagmar Hess (1) · Parameswaran Hari, MD (1) · Peng Liu, M.D. & Ph.D. (1) · Wan-Hong Zhao, MD, PhD (1)
2018 (1)